Philip Morris International Earnings Call Transcripts
Fiscal Year 2026
-
Guidance was reaffirmed despite currency adjustments, with strong demand for smoke-free products driving growth. ZYN ULTRA launches in the U.S. amid regulatory clarity, while IQOS maintains share in Japan and prepares for U.S. entry. Margin improvements and robust cash generation support ongoing investment and shareholder returns.
-
The meeting covered strong 2025 financial results, continued smoke-free transformation, and strategic plans through 2030. All director nominees and proposals, except the shareholder resolution on filter cleanup, were approved. Dividend growth and resilience amid global uncertainty were highlighted.
-
Q1 2026 saw robust growth in smoke-free products, strong pricing, and margin expansion, driving double-digit gains in adjusted operating income and EPS. Guidance for 2026 is reaffirmed, with continued investment in innovation and sustainability, despite regulatory and macroeconomic uncertainties.
-
Smoke-free products now drive over 40% of revenue, with rapid expansion into 106 markets and strong growth in key regions. Financial targets include high single-digit to low-teen smoke-free volume growth, 6–8% organic revenue growth, and $45B operating cash flow by 2028, supporting higher dividends and shareholder returns.
Fiscal Year 2025
-
Reported strong 2025 results with double-digit EPS and operating income growth, driven by robust smoke-free product expansion and margin gains. 2026 guidance anticipates continued top- and bottom-line growth despite tax and regulatory headwinds, with renewed medium-term targets and strong cash flow supporting shareholder returns.
-
Smoke-free products now drive over 40% of sales, with robust growth in ZYN and IQOS across global markets. Margin expansion is supported by premium positioning and scale, while regulatory sentiment is improving and new organizational structures align with business realities.
-
Q3 saw record results driven by strong smoke-free product growth, margin expansion, and robust U.S. ZYN performance, despite elevated investment and promotional costs. Full-year guidance was raised for EPS and cash flow, with continued focus on deleveraging and shareholder returns.
-
Year-end EPS growth is reaffirmed at 13%-15%, driven by strong smoke-free product momentum and margin expansion. ZYN and IQOS continue to grow, with ZYN holding a significant price premium and expanding globally. Regulatory changes and innovation remain key focus areas.
-
H1 2025 saw record smoke-free net revenues, double-digit EPS growth, and margin expansion, with strong performances from IQOS, Zyn, and Veev. Full-year guidance was raised for EPS, revenue, and cash flow, while robust pricing and cost efficiencies offset modest combustible volume declines.
-
Strong growth in smoke-free products is driving revenue and margin expansion, with IQOS, ZYN, and VEEV forming a successful multi-category strategy. U.S. market pilots and regulatory progress support future ambitions, while financial discipline and a progressive dividend policy remain priorities.
-
Q1 2025 saw double-digit growth in revenue, operating income, and EPS, led by strong smoke-free product performance. ZYN, IQOS, and VEEV all posted robust gains, with smoke-free gross margin surpassing 70%. Guidance for 2025 was raised, with continued investment in capacity and deleveraging.
Fiscal Year 2024
-
Delivered strong 2024 results with double-digit growth in revenue, operating income, and EPS, driven by robust performance in smoke-free products, especially IQOS and ZYN. 2025 guidance anticipates continued volume and margin expansion, with investments focused on smoke-free growth.
-
Q3 delivered double-digit organic growth in revenue, operating income, and EPS, driven by strong performance across smoke-free and combustible segments. Full-year guidance was raised for all key metrics, with robust cash flow and continued margin expansion.
-
Stock outperformed peers with strong revenue and EPS growth, driven by NGPs and U.S. expansion. Regulatory challenges like the EU flavor ban are being managed, while capacity expansions aim to restore ZYN's market share. Dividend focus and prudent capital allocation continue.
-
Record H1 growth driven by strong IQOS and ZYN performance, with raised full-year guidance for revenue, operating income, and EPS. Smoke-free products expanded globally, while supply and regulatory challenges persist, especially in the U.S. and Europe.
-
Strong H1 2024 growth is driven by smoke-free products like IQOS and ZYN, with robust financial guidance and margin improvement. Strategic focus is on organic growth, responsible ESG practices, and leveraging the combustible business to fund the transition.